RDR Alert®

Prevalence of anemia in patients with chronic kidney disease on hemodialysis found higher in Mexico than studied populations, with similar contributing factors.

Due to taboo or stigma, patients may not openly discuss their leg ulcers with their providers.

Up to 84% of younger patients note a positive experience with holistic therapeutic approaches to treating sickle cell-related pain.

An expert discusses findings that showed voxelotor (Oxbryta) improved leg ulcers in patients with sickle cell disease.

Vascular electrical stimulation therapy was associated with reduction in vaso-occlusive symptoms.

The 3D-printed implant is patient specific and modeled after the anatomy of the individual.

The suspension is due to recently reported diagnoses of AML and myelodysplastic syndrome in 2 treated patients.

Phase 3 COMET findings show the Sanofi Genzyme product delivered significantly improved efficacy and safety for the rare autosomal disorder.

The indication is the first granted to an ANGPTL3 inhibitor in the US.

Surgeons recommend measures to reduce complications from cholecystectomy and splenectomy in patients with sickle cell disease.

FLT201 is a combination of AAVS3 capsid and a liver-specific promotor to drive the expression of GCasevar85.

New WORLDSymposium findings show a treated patient had 100% reduction in the accumulating fatty substrate associated with the burdensome rare disease after 1 year.

Hydroxyurea therapy was associated with decreased rates of retinal thinning and could be a protective factor.

New findings show that 100% of patients receiving voxelotor 1500 mg group experienced improvements in their leg ulcers—compared to 63% in the placebo group.

Patients with sickle cell disease who are undernourished report higher disease severity and lower health-related quality of life scores.

Two gene therapy techniques in separate, concurrently published trials demonstrate clinical success in mitigating monogenic hemoglobinopathies.

Rodney Wilson, spokesperson from the American Red Cross, offers some final thoughts on how providers can encourage blood donations among their patients.

Elevated tricuspid reguritant velocity levels as a biomarker for SCA severity also marks response to disease modifying treatments.

Encouraging and incentivizing donations is essential to ensuring supplies of all blood types are met.

A spokesperson from American Red Cross discusses the importance of National Blood Donor Month and the challenges faced during the COVID-19 pandemic.

A new study has identified various potential clinical predictors associated with poor outcomes, including mortality, in patients with sickle cell disease.

The indication is the first of its kind for the rare, sometimes quickly fatal disease.

The current literature points to the potential efficacy and safety of the anti-depressant drug, but more research is needed to verify its role in managing pain caused by vaso-occlusive crises.

Alnylam plans to submit a NDA for the orphan drug used to treat hATTR with amyloidosis in adults.

New one-year data makes history as the first to indicate the superiority of a one-injection gene therapy versus Factor VIII prophylaxis.